[go: up one dir, main page]

PE20040464A1 - Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3 - Google Patents

Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3

Info

Publication number
PE20040464A1
PE20040464A1 PE2003000387A PE2003000387A PE20040464A1 PE 20040464 A1 PE20040464 A1 PE 20040464A1 PE 2003000387 A PE2003000387 A PE 2003000387A PE 2003000387 A PE2003000387 A PE 2003000387A PE 20040464 A1 PE20040464 A1 PE 20040464A1
Authority
PE
Peru
Prior art keywords
tract
antagonists
benzimidazolones
substituted
hiperastic
Prior art date
Application number
PE2003000387A
Other languages
English (en)
Inventor
Neng-Yang Shih
Robert G Aslanian
Daniel M Solomon
Pauline C Ting
Kevin D Mccormick
Christopher W Boyce
Jianhua Cao
Qingbei Zeng
Mwangi W Mutahi
Pietro Mangiaracina
Wing C Tom
Michael Y Berlin
Stuart B Rosenblum
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20040464A1 publication Critical patent/PE20040464A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENZIMIDAZOLONAS DE FORMULA I, DONDE LA LINEA PUNTEADA INDICA UN DOBLE ENLACE OPCIONAL, a Y b SON DE 0 A 3; n ES 1, 2 o 3; p ES 1, 2 o 3 SOLO SI, CUANDO M2 ES N, ENTONCES p NO ES 1; r ES 1, 2 o 3 SOLO SI, CUANDO r ES 2 o 3, ENTONCES M2 ES C(R3) Y p ES 2 o 3; A ES UN ENLACE O ALQUILENO(C1-C6); M1 Y M2 SON C(R3) O N; Y ES -C(=O)-, -C(=S)-, -(CH2)q-, -NR4C(=O)-, -C(=O)NR4, ENTRE OTROS, SIEMPRE QUE SI M1 ES N, Y NO ES -NR4C(=O)- o -NH-C(=N-CN)-; Y CUANDO M2 ES N, Y NO ES C(=O)NR4 O -C(=N-CN)-NH; Z ES UN ENLACE, ALQUILENO(C1-C6), ALQUENILENO(C1-C6), -C(=O)-, -CH(CN)- O -CH2C(=O)NR4; R1 ES UNA BENCIMIDAZOLONA R-SUSTITUIDA DE FORMULAS a, b Y ENTRE OTRAS, DONDE R ES H, ALQUILO(C1-C6), HIDROXIALQUILO(C2-C6), HALOALQUILO(C1-C6), N(R30)(R31)-C(O)-ALQUILO(C1-C6), ENTRE OTROS; R2 ES UN HETEROARILO DE 6 MIEMBROS CON 1 O 2 HETEROATOMOS DE N O N-O, O DE 5 MIEMBROS CON 1 A 4 HETEROATOMOS DE N, O o S O ES R32-QUINOLILO, R32-ARILO, ENTRE OTROS.TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS SOLO O EN COMBINACION CON ANTAGONISTAS DE RECEPTORES H1 COMO: LORATADINA, DESCARBOETOXILORATADINA, FEXOFENADINA O CETIRIZINA. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR H3 Y SON UTILES EN EL TRATAMIENTO DE LAS ALERGIAS, AFECCIONES DE LAS VIAS RESPIRATORIAS INDUCIDAS POR ALERGIA Y CONGESTION, ENFERMEDADES CARDIOVASCULARES, DEL TRACTO GASTROINTESTINAL, HIPER E HIPO MOTILIDAD O SECRECION ACIDA DEL TRACTO GASTRO INTESTINAL, TRANSTORNOS DEL SISTEMA NERVIOSO CENTRAL
PE2003000387A 2002-04-18 2003-04-16 Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3 PE20040464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37346702P 2002-04-18 2002-04-18

Publications (1)

Publication Number Publication Date
PE20040464A1 true PE20040464A1 (es) 2004-07-24

Family

ID=29736058

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000387A PE20040464A1 (es) 2002-04-18 2003-04-16 Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3

Country Status (17)

Country Link
US (1) US7220735B2 (es)
EP (1) EP1494671B1 (es)
JP (2) JP4563800B2 (es)
KR (1) KR20040099449A (es)
CN (1) CN100360130C (es)
AR (1) AR040406A1 (es)
AT (1) ATE529112T1 (es)
AU (1) AU2003223631B2 (es)
CA (1) CA2482551C (es)
IL (1) IL164583A (es)
MX (1) MXPA04010172A (es)
MY (1) MY132566A (es)
NZ (1) NZ535764A (es)
PE (1) PE20040464A1 (es)
TW (1) TW200305409A (es)
WO (1) WO2003103669A1 (es)
ZA (1) ZA200407985B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
JP4384918B2 (ja) * 2002-04-18 2009-12-16 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体
NZ535764A (en) * 2002-04-18 2007-10-26 Schering Corp 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists
PT1556354E (pt) * 2002-06-28 2008-04-17 Euro Celtique Sa Derivados de piperazina úteis como agentes terapêuticos para o tratamento da dor
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
CA2523431A1 (en) 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
CA2550012A1 (en) * 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
CA2572075A1 (en) 2004-06-28 2006-01-12 Janssen Pharmaceutica Nv Hetero isonipecotic modulators of vanilloid vr1 receptor
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
CA2599989A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
ATE450526T1 (de) * 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
ES2337728T3 (es) * 2005-06-20 2010-04-28 Schering Corporation Piperidinas sustituidas unidas a carbono y sus derivados utiles como antagonistas de histamina h3.
CA2606004A1 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CA2617557A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US7332604B2 (en) * 2005-09-20 2008-02-19 Schering Corporation 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
JP2009521451A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用な置換アニリン誘導体
PE20071162A1 (es) * 2005-12-21 2007-11-30 Schering Corp Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
EP1962835A2 (en) * 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
MX2008008337A (es) * 2005-12-21 2008-09-03 Schering Corp Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3.
US20070197590A1 (en) * 2006-01-31 2007-08-23 Demong Duane E Substituted dipiperidine ccr2 antagonists
US7728031B2 (en) * 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
US20100210633A1 (en) * 2006-10-12 2010-08-19 Epix Delaware, Inc. Carboxamide compounds and their use
JP2010520201A (ja) * 2007-03-02 2010-06-10 シェーリング コーポレイション ベンズイミダゾール誘導体およびその使用方法
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
EP2215066A1 (en) * 2007-11-01 2010-08-11 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
CA2705138A1 (en) * 2007-11-08 2009-05-14 Sirtris Pharmaceuticals, Inc. Solubilized thiazolopyridines
EP2280766A1 (en) 2007-12-11 2011-02-09 CytoPathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
CA2739668C (en) 2008-01-04 2016-10-11 Schabar Research Associates Llc The use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
EP2376502B1 (en) 2008-12-19 2015-06-17 GlaxoSmithKline LLC Thiazolopyridine sirtuin modulating compounds
NZ604035A (en) 2010-06-04 2015-02-27 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
JP2014114212A (ja) * 2011-03-29 2014-06-26 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
ES2730112T3 (es) 2015-03-09 2019-11-08 Bristol Myers Squibb Co Lactamas como inhibidores de ROCK
JP7281469B2 (ja) * 2018-01-19 2023-05-25 イドーシア ファーマシューティカルズ リミテッド Ｃ５ａ受容体調節剤
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US10639315B1 (en) 2019-05-21 2020-05-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating Alzheimer's disease
AU2019443520A1 (en) * 2019-04-30 2021-12-23 La Pharma Tech Inc. A method of treating mental, behavioral, cognitive disorders
CN110105263A (zh) * 2019-05-13 2019-08-09 常州大学 一种阿米卡星中间体的合成方法
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
KR20230051164A (ko) 2020-07-15 2023-04-17 샤바르 리서치 어소시에이츠 엘엘씨 급성 통증의 치료 및 속쓰림의 중증도 및/또는 위험의 감소를 위한 이부프로펜 및 파모티딘으로 구성된 단위 경구 투여 조성물
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
WO2022268935A2 (en) * 2021-06-23 2022-12-29 F. Hoffmann-La Roche Ag Novel process
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
JP2026502847A (ja) * 2022-12-23 2026-01-27 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害剤の調製のためのプロセス

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0730037B2 (ja) 1987-03-13 1995-04-05 第一製薬株式会社 ピリミジニルプロピオン酸誘導体
JP2807577B2 (ja) * 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP3859738B2 (ja) * 1993-05-26 2006-12-20 大日本住友製薬株式会社 キナゾリノン誘導体
FR2725986B1 (fr) * 1994-10-21 1996-11-29 Adir Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
GB9521781D0 (en) * 1995-10-24 1996-01-03 Merck Sharp & Dohme Therapeutic agents
WO1997019074A1 (en) * 1995-11-17 1997-05-29 Hoechst Marion Roussel, Inc. Substituted 4-(1h-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
JP3638289B2 (ja) 1996-08-16 2005-04-13 シェーリング コーポレイション ヒスタミンレセプターアンタゴニストの組み合わせを用いる上気道アレルギー性応答の処置
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6506756B2 (en) * 2000-09-20 2003-01-14 Schering Corporation Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2002072570A2 (en) 2001-03-13 2002-09-19 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
NZ535764A (en) * 2002-04-18 2007-10-26 Schering Corp 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists

Also Published As

Publication number Publication date
ATE529112T1 (de) 2011-11-15
AU2003223631A1 (en) 2003-12-22
JP2005529161A (ja) 2005-09-29
US20040048843A1 (en) 2004-03-11
JP4563800B2 (ja) 2010-10-13
NZ535764A (en) 2007-10-26
IL164583A (en) 2010-05-17
US7220735B2 (en) 2007-05-22
AR040406A1 (es) 2005-04-06
JP2006206603A (ja) 2006-08-10
TW200305409A (en) 2003-11-01
KR20040099449A (ko) 2004-11-26
ZA200407985B (en) 2005-10-19
MY132566A (en) 2007-10-31
CN1658875A (zh) 2005-08-24
MXPA04010172A (es) 2005-02-03
CA2482551C (en) 2009-08-11
WO2003103669A1 (en) 2003-12-18
CA2482551A1 (en) 2003-12-18
EP1494671B1 (en) 2011-10-19
AU2003223631B2 (en) 2006-07-20
CN100360130C (zh) 2008-01-09
EP1494671A1 (en) 2005-01-12
IL164583A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
PE20040464A1 (es) Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3
CN107973790A (zh) 杂环fxr调节剂
Raj et al. Synthesis of 1H-1, 2, 3-triazole linked β-lactam–isatin bi-functional hybrids and preliminary analysis of in vitro activity against the protozoal parasite Trichomonas vaginalis
AR033528A1 (es) Diamino derivados sustituidos novedosos utiles como antagonistas de la motilina
NO180488B (no) Benzoisothiazol og benzoisoksazol-3-karboksamider og deres bruk til fremstilling av medikamenter
DE602005008558D1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
ES2348621T3 (es) Derivados de 1-sulfonilindol, su preparación y su uso como ligandos de 5-ht6.
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
JP2017522379A (ja) 置換２−チオキソ−イミダゾリジン−４−オン及びそのスピロ類似体、抗癌有効成分、医薬組成物、医薬製剤、並びに前立腺癌の治療法
Alagarsamy et al. Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1, 2, 4] triazolo [4, 3-a] quinazolin-5-ones as new class of H1-antihistaminic agents
MX2009005507A (es) Derivados de espiro-piperidina.
AR038704A1 (es) Derivados de tiazol como antagonistas del receptor nyp
ATE318266T1 (de) 3-substituierte chinolin-4- carbonsäureamidderivate als nk-3- und nk-2- rezeptorantagonisten
GT200500281A (es) Compuestos organicos.
DE69626321D1 (de) Substituierte 4-(1h-benzimidazol-2-yl-amino)piperidine zur behandlung allergischer erkrankungen
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
ES2222829B1 (es) Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
PE20061108A1 (es) Derivados de aril 1,4-pirazina sustituidos
AR052332A1 (es) Derivados de benzdioxanpiperazina con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del snc

Legal Events

Date Code Title Description
FC Refusal